Background image: diffusion MRI, also referred to as diffusion tensor imaging or DTI, of the human brain
World Alzheimer’s Day takes place every year on 21 September, integral to World Alzheimer’s Month which is an international campaign, led by the Alzheimer’s society to raise awareness and highlight issues faced by people affected by dementia.
Dementia is one of the biggest health challenges we face with nearly 50 million people living with dementia worldwide – a number which continues to grow, causing devastation for patients, their loved ones, and carers. Unfortunately, there are no drug treatments that can cure Alzheimer’s disease and those that are available currently do not slow down or stop the progression of underlying disease in the brain – however they can help ease symptoms or slow down the disease in some people.
We’re passionate about working in collaboration with and supporting researchers who are working towards developing new treatments that could lead to a potential cure for Alzheimer’s disease.
Illustration of neurons showing oligodendrocytes in orange bound to the axon of the neuron
Antibody stained hippocampus, a section of the brain where neurons develop in adults
Alzheimer’s disease is classically characterized by misfolded aggregates of Aß and tau proteins, forming plaques and tangles in the brain. However, emerging evidence indicates that neuroinflammation, mediated by activated glial cells, may also play a fundamental role in Alzheimer’s disease pathogenesis. Consequently, understanding the interplay between the immune and nervous systems might be the key to prevention or delay of several neurodegenerative diseases, including Alzheimer’s.
We are actively supporting researchers who are working to enhance understanding of the pathological processes involved in disease development and progression in order to help drive the evolution of innovative treatments. We are committed to continuing developing innovative reagent solutions and making them available to the global research community to support research efforts to tackle the challenge of dementia around the world.
Spotlight on Neuroscience
To help support cutting- edge neuroscience investigation, we have collated a series of interactive digital sessions dedicated to highlighting the latest breakthroughs.
With topics spanning embryonic brain development and regulated neurogenesis, neurogenesis’s links to behavior, lipid metabolism, and development of neurological disorders, neurodevelopment disorders during pregnancy and early years of childhood, intracellular trafficking, age-related degeneration issues involving memory and motor function loss and understanding brain rewiring.
In creating this month of unique digital activities, it is our hope to enable the dementia research community to gain additional insights into approaches impacting the field through talks by thought leaders from across both industry and academia, stimulating discussions and thought-provoking Q&As.
Confirmed Speakers
Background image: Cortical neurons and glia cells in culture. Green: Alpha-Tubilin-Alexa 488. Blue: Nucleic acids, DAPI. Image Courtesy of Sabine Thomas and Prof. Dr. Michael Kiebler, Brain Research Center, Neuronal Cellular Biology, Medical University of Vienna, Austria. Credit: Zeiss Microscopy
“I have seen the devastation caused by Alzheimer’s first-hand as a daughter who lost her father to this disease in recent years, and professionally through 20+ years spent in the industry working for pharmaceutical companies focused on developing new treatment approaches. I am incredibly proud of the important role that Abcam is playing by providing researchers with ready access to innovative tools to drive their important discovery journeys, that are providing renewed hope for patients, their families and those who care for loved ones with Alzheimer’s.”
Ally Hughes, Senior Director of Strategy – Neuroscience, Abcam
“I have seen the devastation caused by Alzheimer’s first-hand as a daughter who lost her father to this disease in recent years, and professionally through 20+ years spent in the industry working for pharmaceutical companies focused on developing new treatment approaches. I am incredibly proud of the important role that Abcam is playing by providing researchers with ready access to innovative tools to drive their important discovery journeys, that are providing renewed hope for patients, their families and those who care for loved ones with Alzheimer’s.”
Ally Hughes, Senior Director of Strategy – Neuroscience, Abcam
RELATED CONTENT
Hear from Professor Michael Heneka of the University of Bonn and the German Center for Neurodegenerative Diseases (DZNE) on Alzheimer’s pathology, inflammation, and why biomarkers of neuroinflammation are critical to help predict treatment responses.
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul